// search index for WYSIWYG Web Builder
var database_length = 0;

function SearchPage(url, title, keywords, description)
{
   this.url = url;
   this.title = title;
   this.keywords = keywords;
   this.description = description;
   return this;
}

function SearchDatabase()
{
   database_length = 0;
   this[database_length++] = new SearchPage("index.php", "Rodos BioTarget GmbH", "rodos biotarget gmbh rbt is privately held venture capital funded biotechnology company based in hannover germany holds novel cell specific nanocarrier called the targosphere® this targeted drug delivery system addresses type lectin receptors clrs on surface of professional antigen presenting cells apcs whitch allows for development potent immunotherapies as these most crucial immune initiate responses well connect innate and adaptive branches immunity importantly harnesses an evolutionarily ancient receptor family by taking advantage whose proper biological function consists binding internalizing pathogens via their peculiar carbohydrate decoration same token enters target cells’ endolysosomal which creates broad spectrum medical opportunities depending respective payload options platform technology divide into two principal arms to induce numerous apc driven protective or therapeutic eradicate cellular infectious pathogen reservoirs permits restoration competence variety disease states innovative interventions against various diseases cancers collaborates with partners biotech pharmaceutical industries we also strives enabling lifecycle management already approved drugs immunomodulators employing contact imprint disclaimer sitemap bookmark page hrb handelsregister steuer nr tax no de262938939 ustid vat latest news meet scientific publications may nbsp receives approval zim grant area hepatitis treatment bmwi federal ministry economy april malaria vaccination frontier program university heidelberg’s cluster excellence october november presents at st annual meeting american association study liver aasld boston ma usa “low serum vitamin nash patients antifibrogenic properties vitro implications july invited present th seed4money investment forum frankfurt main june sponsorship its general assembly bpi german industry berlin dr gieseler workshop tumor dendritic society immunology göttingen “c nanocarriers specifically addressing priming cells” nominated “next wave company” bio€quity europe zurich switzerland participates high tech partnering conference bonn furch deutsche biotechnologietage “targospheres® vaccination” selected join pool companies equity spring deutsches eigenkapital frühjahr dresden organized kfw bank march charité entrepreneurship summit hosted stiftung foundation bio barcelona december european commission ebe biopharmaceutical enterprises discuss “industry access finance small medium sized europe” brussels vienna rk marquitan schlattjan sowa bechmann lp timm roggendorf gerken friedman sl canbay hepatocyte apoptotic bodies encasing nonstructural hcv proteins amplify hepatic stellate activation chronic viral hepatol press jochum kocabayoglu kassalik saner paul cytokeratin modification meld score improves prediction spontaneous survival after acute injury associated editorial samuel ichai prognosis indicator failure there place death markers? dechêne el fouly baba dries elevated stiffness hepatology epub link jp kahraman erhard wedemeyer emons feldkamp apoptosis cd36 fatty acid translocase upregulation non alcoholic steatohepatitis int yildiz meziletoglu schlensak fingas cd ha major histocompatibility complex class related chains mic role nonalcoholic gao natural killer group member ligands good bad? gawlista fiedler manka fh immediate entecavir inhibits virus replication potentially sequelae digestion home about us consultants advisory board investors history research focus applications rbt’s science amp partnerships academic relationships collaborations media releases awards events downloads faq careers search ", "");
   this[database_length++] = new SearchPage("about.html", "Rodos BioTarget GmbH - About us", "rodos biotarget gmbh about us ", "");
   this[database_length++] = new SearchPage("overview.html", "Rodos BioTarget GmbH - overview", "rodos biotarget gmbh overview rbt is an early stage privately held venture capital funded biotechnology company based in hannover germany has developed novel pathway towards immune reconstitution and disease control employing cell targeted nanocarriers ‘targospheres®’ to channel potent bioactive agents into intracellular pathways of cells that direct the antigen specific response this permits restoration competence variety states as well providing innovative interventions against various infectious diseases cancers rbt’s initial development program directed at eliminating reservoirs human immunodeficiency hepatitis viruses restoring hepatocellular carcinoma colorectal adenocarcinoma having achieved effective nanocarrier targeting technology presenting also collaborates with partners pharmaceutical industry achieve improved vaccine responses other infections additionally partnering established enterprises broad application platform shall be applied life cycle management improving efficacy existing treatments multiple entities thereby broadening its overall marketing potential vision mission leading international drug discovery will provide first significantly enhance immunological defence autoimmune disorders by enabling delivery centre strives create clinically meaningful medicines order minimize toxicity improve quality build commercial value for shareholders employees high performance organization fostering team spirit personal professional integrity successfully employ proprietary targospheres® within system immunity about contact imprint disclaimer sitemap bookmark page home nbsp us consultants scientific advisory board investors history research therapeutic focus applications science amp lifecycle publications partnerships academic relationships collaborations media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("management.html", "Rodos BioTarget GmbH - management", "rodos biotarget gmbh management contact imprint disclaimer sitemap bookmark this page dr marcus furch chief executive officer ceo robert gieseler von der crone scientific cso for short bio move over photography home about nbsp us consultants advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers co founder chemist by training received his phd in the area of biochemistry from university heidelberg followed an mba maastricht business school during career he worked as scientist international renowned laboratories germany max planck institute medical well hannover france cnrs montpellier spain basque country san sebástian united states scripps la jolla california consultant at brazilian kienbaum subsidy böge consultores são paulo advised chemical pharmaceutical companies entering latin american markets five years fresenius se global player pharmaceuticals devices was involved numerous licensing transactions while working with nalucon interim manager advisor to both life industry joined founders rbt biologist immunology when georg august göttingen among those elucidating ontogeny myeloid dendritic cells developed gold standard vitro differentiation protocol these apcs scolaro joint hiv aids program st vincent center southern los angeles usa subsequently did commissioned work merck frosst centre quebec canada then led preclinical programs on solid organ transplantation oncology autoimmunity essen public non profit together team scientists their provided foundation proprietary parallel held position adjunct professor florida supervised northern europe division laboratorios leti has been appointed coordinator hepatitis other liver diseases ", "");
   this[database_length++] = new SearchPage("consultant.html", "Rodos BioTarget GmbH - management", "rodos biotarget gmbh management consultants contact imprint disclaimer sitemap bookmark this page dr michael scolaro chief medical consultant jörg ruppert business development for short bio move over photography louis capozzi mba public relations robert gieseler von der crone co founder and cso is biologist by training specialized on immunology as of in received his phd focusing basic research human rodent apcs he was among those identifying the ontogeny myeloid dendritic cells developed key vitro differentiation protocol these joined worked joint hiv aids program st vincent center university southern california school los angeles usa subsequently did commissioned work merck frosst centre therapeutic quebec canada then led pre clinical programs solid organ transplantation oncology autoimmunity at georg august göttingen hospital essen germany five years scientist non profit institute together with team scientists their provided foundation proprietary technology rbt also held position adjunct professor florida prior to founding supervised northern europe amp division medium sized european pharmaceutical company served coordinator hepatitis other liver diseases home about nbsp us scientific advisory board investors history focus applications rbt’s science lifecycle publications partnerships academic relationships collaborations partnering media press releases awards events downloads faq careers physician md more than experience psychiatry neurology internal medicine infectiology virology early contributed today’s state art combination therapy treatment haart senior investigator let there be hope former director principal contributor studies infectious appointed associate investor when investigations into intracellular targeting infected sense antisense tat gene publicly listed biotech cytel corp san diego three drug utilizing antigen presentation technologies after marketing german subsidiary large corporation icn biomedicals became partner eight venture capital firm heidelberg innovation an investment manager specializing financing developing selling biotechnology start up companies currently holds international sales diagnostics journalism graduate finance financial writer wrote dozens corporate annual reports acted speechwriter ceos handled communications from small firms fortune global corporations went hill knowlton later bankers trust new york managing wide banking acquisitions autex inc headed office ketchum vice president aetna life casualty managed person department budgeted million during time chairman ceo manning selvage lee tripled size one leaders its field named ‘agency year’ until publicis group world’s fourth largest holding where oversaw all group’s billion pr businesses serves has extensive crisis issues such american association upjohn hoffman la roche gillette philips nike westinghouse accounting industry others frequently contributes acts spokesman speaker ", "");
   this[database_length++] = new SearchPage("scientific_advisory_board.html", "Rodos BioTarget GmbH - advisory board", "rodos biotarget gmbh advisory board scientific contact imprint disclaimer sitemap bookmark this page ali canbay md professor gastroenterology amp hepatology experimental university of essen medical school germany link advisor on viral hepatitides hepatocellular carcinoma and other liver diseases scott friedman mount sinai center new york ny usa the role hepatic stellate cells ann kristin mueller phd group leader parasitology microbiology genetics heidelberg medicine malaria parasitic hinrich peters immunology oncology georg august göttingen cancer vaccination with dendritic rolf schlemminger general visceral surgery reinhard nieter hospital wilhelmshaven transplantation microsurgical techniques schubert pharmaceutical chemistry albert ludwigs freiburg development validation targeted drug delivery systems home about nbsp us management consultants investors history research therapeutic focus applications rbt’s science technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("investors.html", "Rodos BioTarget GmbH - investors", "rodos biotarget gmbh investors about high tech gruenderfonds htgf invests venture capital in young opportunity technology companies implementing promising research results an entrepreneurial manner the start up are expected to lead their amp projects production of prototype nbsp “proof concept” or market launch by means seed financing eur has fund volume around million public private partnership federal ministry for economics and kfw bank group as well six industrial groups basf deutsche telekom siemens robert bosch daimler carl zeiss link hannover innovation fonds enjoyventure hif is regional initiated department business development city region into early stage ventures fields automotive optical technologies ict life science healthcare energy managed manager led entrepreneurs which offers funding innovative currently manages four funds with total approx contact imprint disclaimer sitemap bookmark this page home us management consultants scientific advisory board history therapeutic focus applications rbt’s lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("history.html", "Rodos BioTarget GmbH - history", "rodos biotarget gmbh history rbt emanated as start up from the non profit let there be hope medical research institute in beverly hills california one major focus of this organization was to devise and develop novel treatments for hiv aids these investigations led technologies addressing intact infectious within certain reservoir cells however it became soon apparent that actually represent platforms whose potentials may extend far beyond related patent applications were then submitted usa eu japan canada once founded hannover germany by some inventors purchased ip received three business plan prizes awards first year after inception rbt’s developmental lead indication remained due additional highly promising data on hcv hepatitis well even greater epidemiological impact chronic its sequelae such hepatocellular carcinoma viral disease is now moreover we have recognized our also enable multiple protective therapeutic purposes result development pipeline currently comprises targosphere® delivered eradicating cellular reservoirs other infections dependent vaccination approaches various cancers malaria which cancer protein vaccines are administered furthermore has successfully completed pilot study area specific immunotherapy treating allergic diseases contact imprint disclaimer sitemap bookmark page home about nbsp us management consultants scientific advisory board investors science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases events downloads faq careers ", "");
   this[database_length++] = new SearchPage("research_development.html", "Research and Development", "research and development home about nbsp us management consultants scientific advisory board investors history therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers contact ", "");
   this[database_length++] = new SearchPage("therapeutic_focus_and_applications.html", "Therapeutic  Focus and Applications", "therapeutic focus and applications nbsp amp in brief rbt is developing carbohydrate targeted nanocarrier termed the targosphere® has been shown to encapsulate active pharmaceutical ingredients apis comprising peptides proteins large protein adducts nucleic acids small molecular compounds spanning range of weights from approx kda this drug delivery system specifically addresses type lectin receptors clrs on myeloid apcs immature mature dendritic cells tissue macrophages blood monocytes liver resident cell populations sinusoidal endothelial hepatic stellate possibly plasmacytoid inlicensed nih virucidal that highly potently bind agglutinate inactivate all rna dna viruses tested thus far rbt05 rbt’s development pipeline does not act mitogenic mutagenic carcinogenic or immunogenic when delivered via able harbored within reservoir so trans infection such completely abrogated we believe it will be imperative complement current gold standard therapies for hcv hiv with treatment as close gaps impede heal these diseases seven day linear dose escalation study lewis lew rat model neither mock loaded targospheres® nor encapsulated free caused any systemic organ specific toxicity same animal have also seen preliminary evidence successful crossing brain barrier subsequent targeting activated microglia astrocytes are known express some key advantages by binding harnesses an ancient family remained conserved throughout evolution receptor uptake pathogens serves one most stable pillars innate adaptive branches immunity alike guarantees steadfast mode therapy may enter expressing even late stages disease usp compared conventional treatments general target specificity no resistance due lack clr mutation great variance payloads inexpensive opposed antibody ligand dependent increased effective forms index reduced cycles greater patient compliance improved cost benefit ratio quality life payload being into viral virus agglutinates intracellular virions their envelope’s largely immutable decoration hits at true ‘achilles heel’ they cannot evade contrast solely replication transcription translation genomes currently comprises eradicating cellular reservoirs hepatitis aids well vaccination approaches various cancers malaria which novel cancer vaccines administered furthermore successfully completed pilot area immuno treating allergic further information industrial world estimated million people infected common global instances acute evolves chronic devastating short term long disabilities high mortality rate its serious sequelae include cirrhosis failure hepatocellular carcinoma typically infects hepatocytes however enters other exploited importantly carry surface serve sites recognition employed address both actively propagates rodos biotarget conceived approach important addition state art reading szabo lotz paska kiss schaff new data pathol oncol res according unaids report epidemic around adults children were living end newly figure includes aged younger had left behind orphans under years age who lost parents cd4 helper reside where providing continuous replicates spreads numerous immune causing vigorous propagation destruction eventually generalized immunodeficiency leading mediated similar described again offers hope many patients offer relief whom only partly eliminated steinbrook engl med gmbh contact imprint disclaimer sitemap bookmark page home about us management consultants scientific advisory board investors history research science technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("RBT_science_and_technology.html", "RBT_science_and_technology", "rbt science and technology current modes of drug delivery burden the entire body with high concentrations this is due to fact that only small fraction active pharmaceutical agent reaches its target thus bearing risk toxic cellular organ specific or systemic side effects such collateral damage can be considerably reduced even excluded by employing targeted systems effectively reach those cell populations in which ingredient supposed unfold nbsp activity rbt’s targosphere® for well established system addresses all type lectin receptors clrs as prominently cd209 cd sign specifically efficiently delivering therapeutic payloads clr positive have been shown reached are myeloid antigen presenting cells apcs comprise immature mature dendritic blood monocytes tissue macrophages ii sinusoidal endothelial hepatic stellate liver evidentially most important class immune they not initiate direct responses but also responsible linking adaptive innate branches attractive addressing these technologies open up possibility developing new highly focused vaccinations therapies infectious malignant chronic inflammatory parasitic autoimmune diseases moreover addition essential eliminating reservoirs hcv hiv because both viruses known form sanctuaries from continuously trans infect resident circulating viral propagation occurs additionally enable controlled compounds into apc there clear development potential substantially enhancing efficacy existing approved drugs currently applied non manner may show significant evidence generalized toxicities selectively shuttling biologically substances novel vaccines rbt´s rodos biotarget gmbh contact imprint disclaimer sitemap bookmark page home about us management consultants scientific advisory board investors history research focus applications amp lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("life_cycle_management.html", "Life Cycle Management", "life cycle management rbt also addresses the needs of many pharmaceutical companies to fill their pipelines with new products and or extend lifecycle drugs which are nearing expiry blockbuster patents emerging drug delivery technologies aim improve measures safety efficacy convenience compliance in both existing candidates will period patent protection for reformulations currently marketed chronic diseases where patient surrounding dosing strategies ease administration limit market growth amp novel applications open door methods reformulating failed discontinued elimination unfavorable toxic side effects potential rbt’s technology cell specific therapeutic agents lead treatment options that do not exist by providing targeted mechanism addressing antigen presenting cells targosphere® offers maximize any agent relies on being delivered immune achieving effect while minimizing risk harmful debilitating effectiveness this methodology is expected reduction frequency dosaging as well concurrent increase success rates over extended time frames allow an improved cost benefit ratio quality rodos biotarget gmbh contact imprint disclaimer sitemap bookmark page home about nbsp us consultants scientific advisory board investors history research development focus science publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("publications.html", "Unbenannte Seite", "unbenannte seite home about nbsp us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers contact ", "");
   this[database_length++] = new SearchPage("scientific_pub.html", "Scientific Publications", "scientific publications rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page nbsp gieseler rk marquitan schlattjan sowa bechmann lp timm roggendorf gerken friedman sl canbay hepatocyte apoptotic bodies encasing nonstructural hcv proteins amplify hepatic stellate cell activation implications for chronic hepatitis viral hepatol in press jochum kocabayoglu kassalik saner paul cytokeratin based modification of the meld score improves prediction spontaneous survival after acute liver injury associated editorial samuel ichai prognosis indicator failure is there place death markers? dechêne el fouly baba dries with elevated stiffness and hepatology may epub link jp kahraman erhard wedemeyer emons feldkamp apoptosis cd36 fatty acid translocase upregulation non alcoholic steatohepatitis int april yildiz meziletoglu schlensak fingas cd ha major histocompatibility complex class related chains mic novel role nonalcoholic gao natural killer group member its ligands disease good or bad? gawlista fiedler manka fh immediate treatment entecavir inhibits virus replication potentially sequelae digestion rbt´s target cells dendritic antigen presenting pdf infectious diseases hepatitides ii hiv aids apc targeting autoimmunity graves cancer kaposi sarcoma melanoma granular myoblastoma select all home about us management consultants advisory board investors history research development therapeutic focus applications rbt’s science amp technology lifecycle partnerships academic relationships company collaborations partnering media releases awards events downloads faq careers latest ", "");
   this[database_length++] = new SearchPage("partnerships.html", "Partnerships", "partnerships rbt seeks opportunities to partner and form alliances with biotechnology pharmaceutical companies as well outstanding investigators from universities scientific institutions rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page home about nbsp us management consultants advisory board investors history research development therapeutic focus applications rbt’s science amp technology lifecycle publications academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("academic_relationships.html", "University Relationships", "university relationships academic in addition to the partners listed under scientific advisory board rbt collaborates with various whose knowledge and experience is at cutting edge of their areas expertise these are alphabetical order mike boysen phd professor organic chemistry carbohydrate leibniz hannover germany gero hilken assoc laboratory animal care handling general zoology hospital essen martin holzer pharmd group leader pharmaceutical technology albert ludwigs freiburg reinhard jahn neurobiology max planck institute for biophysical göttingen guido marquitan dmsc molecular biology experimental gastroenterology medical school margarete odenthal pathology cologne regine süss klaus überla md virology ruhr bochum rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page home about nbsp us management consultants investors history research development therapeutic focus applications rbt’s science amp lifecycle publications partnerships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("company_collaborations.html", "Company Collaborations", "company collaborations since rbt has entered into various with both international and national biotech pharmaceutical companies to apply adapt targospheres® for their specific applications rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page home about nbsp us management consultants scientific advisory board investors history research development therapeutic focus rbt’s science amp technology lifecycle publications partnerships academic relationships partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("partnering.html", "partnering", "partnering within the biopharmaceutical industry is key component of rbt’s growth strategy and focused onto pipeline opportunities our targosphere® platform we seek to create strong medical scientific commercial as well cultural fit with partners drive outstanding value for all parties specifically rbt seeks out license applications vaccinations or treatments in following areas infectious diseases malignant chronic inflammatory autoimmune atopic are also ready co develop diagnostics contact business development biotargeting eu rodos biotarget gmbh imprint disclaimer sitemap bookmark this page home about nbsp us management consultants advisory board investors history research therapeutic focus science amp technology lifecycle publications partnerships academic relationships company collaborations media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("media.html", "Media", "media home about nbsp us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering press releases awards events downloads faq careers contact ", "");
   this[database_length++] = new SearchPage("press_releases_news.html", "Press Releases and News", "press releases and news rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page nbsp may receives start up financing by high tech gruenderfonds hannover innovations fonds eng ger home about us management consultants scientific advisory board investors history research development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("awards.html", "Awards", "awards rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page nbsp april venture lounge life sciences science4life cup plug amp work performance location home about us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases events downloads faq careers ", "");
   this[database_length++] = new SearchPage("events.html", "Events", "events rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page nbsp october to november rbt presents at the st annual meeting of american association for study liver diseases aasld in boston ma usa on “low serum vitamin nash patients and antifibrogenic properties vitro implications july is invited present th seed4money investment forum frankfurt main june receives sponsorship its technology platform lifecycle management general assembly bpi german pharmaceutical industry berlin germany may dr gieseler workshop tumor vaccination with dendritic cells society immunology göttingen “c type lectin targeted nanocarriers specifically addressing priming cells” nominated “next wave company” bio€quity europe zurich switzerland april participates high tech partnering conference bonn furch deutsche biotechnologietage “targospheres® enabling drug delivery vaccination” selected join pool presenting companies equity spring deutsches eigenkapital frühjahr dresden organized by kfw development bank march charité entrepreneurship summit hosted stiftung foundation bio barcelona december european commission ebe biopharmaceutical enterprises discuss “industry access finance small medium sized europe” brussels vienna licensing opportunities bioeurope milano link lower saxon life science day discussion ‘what can be done against global hiv tb hcv epidemics?’ pdf euro biotech session gcc3 international germinal center significant reduction cell infectivity ctl con reservoir apcs september investor sciences chemistry targospheres nd science4life fair more than from all over will attend between jahrhunderthalle hoechst provides an interested audience germany’s most innovative products services creative brains behind them available deal making austria largest serving biotechnology annually attracts leading dealmakers pharma along exciting emerging produced support it considered “must attend” event home about us consultants scientific advisory board investors history research therapeutic focus applications rbt’s amp publications partnerships academic relationships company collaborations media press releases awards downloads faq careers ", "");
   this[database_length++] = new SearchPage("downloads.html", "Events", "events downloads rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page nbsp home about us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards faq careers ", "");
   this[database_length++] = new SearchPage("faq.html", "Frequently Asked Questions (FAQ)", "frequently asked questions faq to be added soon rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page home about nbsp us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads careers ", "");
   this[database_length++] = new SearchPage("careers.html", "Career", "career open positions project manager scientist research with chemical degree life science contact for detailed job profiles info biotargeting eu opportunities rodos biotarget gmbh imprint disclaimer sitemap bookmark this page home about nbsp us management consultants scientific advisory board investors history and development therapeutic focus applications rbt’s amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("contact.php", "Contact", "contact address rodos biotarget gmbh medical park hannover feodor lynen str germany tel fax nbsp info biotargeting eu imprint disclaimer sitemap bookmark this page name phone email country select your afghanistan aland islands albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia herzegovina botswana bouvet island brazil british indian ocean territory brunei darussalam bulgaria burkina faso burundi cambodia cameroon canada cape verde cayman central african republic chad chile china christmas cocos keeling colombia comoros congo cook costa rica cote ivoire croatia cuba cyprus czech denmark djibouti dominica dominican ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland faroe fiji finland france french guiana polynesia southern territories gabon gambia georgia ghana gibraltar greece greenland grenada guadeloupe guam guatemala bissau guyana haiti heard mcdonald vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati south korea north kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall martinique mauritania mauritius mayotte mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands antilles new caledonia zealand nicaragua niger nigeria niue norfolk northern mariana norway oman pakistan palau palestinian panama papua paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena kitts nevis lucia pierre miquelon vincent the grenadines san marino sao tome principe saudi arabia senegal serbia montenegro seychelles sierra leone singapore slovakia slovenia solomon somalia africa spain sri lanka sudan suriname svalbard jan mayen swaziland sweden switzerland syrian arab taiwan tajikistan tanzania thailand timor leste togo tokelau tonga trinidad tobago tunisia turkey turkmenistan turks caicos tuvalu uganda ukraine united emirates kingdom states uruguay uzbekistan vanuatu venezuela vietnam virgin wallis futuna western sahara yemen zambia zimbabwe message javascript muss im browser aktiviert sein um google maps anzeigen zu können home about us management consultants scientific advisory board investors history research development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("map_zoom.html", "Map", "map rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page javascript muss im browser aktiviert sein um google maps anzeigen zu können home about nbsp us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("succes.html", "Contact", "contact address rodos biotarget gmbh medical park hannover feodor lynen str germany tel info biotargeting eu imprint disclaimer sitemap bookmark this page thank you the message was sent successfully home about nbsp us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("error.html", "Contact", "contact address rodos biotarget gmbh medical park hannover feodor lynen str germany tel info biotargeting eu imprint disclaimer sitemap bookmark this page sorry an error occurred the message was not sent home about nbsp us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("imprint.html", "Imprint", "imprint the content of this website has been carefully verified and rbt takes seriously need to ensure is updated when appropriate however we cannot guarantee for completeness correctness most current up date aspects any information contained in or accessible via embedded links biotargeting eu de org by rodos biotarget gmbh issued feodor lynen str hannover germany managing board dr marcus furch ceo robert gieseler von der crone cso fax email info web www concept design contact disclaimer sitemap bookmark page home about nbsp us management consultants scientific advisory investors history research development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers ", "");
   this[database_length++] = new SearchPage("disclaimer.html", "Imprint", "imprint disclaimer legal statement the sole purpose of biotargeting eu website is to provide public with general information about activities rodos biotarget gmbh by accessing this you are deemed take notice and accept contents no warranty liability while attempting include accurate up date we make representations or warranties express implied as accuracy completeness provided on disclaim any for use site linked it may change including at time without but does not assume responsibility update all users agree that access their own risk neither nor other party involved in creating producing delivering from shall be liable manner whatsoever direct incidental consequential indirect punitive damages arising out your inability errors omissions content thereof forward looking expressly implicitly contain specific statements limitation containing words “expects” “believes” “anticipates” similar expressions such subject known unknown risks uncertainties factors which result substantial divergence between actual results financial situation development performance company those explicitly presumed these against background readers should place undue reliance assumes adapt them future events developments non confidentiality want receive confidential proprietary through its therefore please note communication transmitted via sending material reproduction publication posting referrals links internet sites convenience do opinion third websites part our control responsible availability external endorse warrant guarantee products services described offered copyright contained referenced therein informational purposes only retransmission text pictures prohibited request permission reproduce addressed webmaster applicable law operated maintained claims associated terms conditions governed exclusively laws federal republic germany contact sitemap bookmark page home nbsp us management consultants scientific advisory board investors history research therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships collaborations partnering media press releases awards downloads faq careers ", "");
   this[database_length++] = new SearchPage("sitemap.html", "Sitemap", "sitemap rodos biotarget gmbh contact imprint disclaimer bookmark this page index about overview management consultant scientific advisory board investors history research development therapeutic focus and applications rbt science technology life cycle publications pub partnerships academic relationships company collaborations partnering media press releases news awards events downloads faq careers map zoom home nbsp us consultants rbt’s amp lifecycle ", "");
   this[database_length++] = new SearchPage("(master).html", "Rodos BioTarget GmbH", "rodos biotarget gmbh ", "");
   this[database_length++] = new SearchPage("(nav).html", "Rodos BioTarget GmbH", "rodos biotarget gmbh home about nbsp us management consultants scientific advisory board investors history research and development therapeutic focus applications rbt’s science amp technology lifecycle publications partnerships academic relationships company collaborations partnering media press releases awards events downloads faq careers contact ", "");
   this[database_length++] = new SearchPage("(nav2).html", "Rodos BioTarget GmbH", "rodos biotarget gmbh contact imprint disclaimer sitemap bookmark this page ", "");
   return this;
}